Vaccinated people with a history of mental health disorders including bipolar disorder, psychosis, and anxiety, have a 24% increased risk of contracting COVID-19, a new study reports.
Anosmia, the loss of the sense of smell which is a common symptom of COVID-19, may be a secondary consequence of immune system inflammation rather than a direct action of the virus.
Camostat mesylate, an oral medication commonly prescribed to treat pancreatitis, reduces both the loss of smell and taste in those with COVID-19 infection.
The repetitive nature of days we faced during the COVID-19 lockdowns may have made our memories and time perception murky. Researchers report on how COVID-19 has impacted our memory, causing a pandemic memory fog.
COVID-19 infection leaves a gene expression signature in the dorsal root ganglia which persist after the virus has cleared. The signature matched other gene expression patterns seen in pain caused by other conditions.
Low testosterone and high estrogen in men are linked to an increased risk of severe COVID-19 infection. Researchers report smaller ring finger length in men, a sign of lower testosterone, was a predictor of severe COVID infection and an increased risk of hospitalization after contracting the virus.
A number of patients who contracted COVID-19 in the early months of the pandemic reported symptoms of neuropathy, including pain, tingling sensations, and numbness that lasted up to three months after recovery. The findings suggest COVID-19 may have lingering effects on peripheral nerves.
BGE-175, an oral drug that reverses multiple aspects of immune aging effectively prevents death in mouse models of COVID-19.
During the early stages of the COVID pandemic, one in three new mothers reported experiencing postpartum depression, while 1 in 5 had symptoms of major depression. The risks were higher in mothers who formula-fed their infants, and in those whose children were in neonatal ICU.